U.S. Markets
Elevance (ELV) notes that it remains confident in returning to "at least" 12% adjusted EPS growth in 2027, citing progress across the portfolio
StockNow breaking-news AI analysis
Elevance Health maintains its 12% EPS growth target for 2027, leveraging AI-driven efficiency, Medicare Advantage margin recovery, and strong Commercial segment demand to overcome 2026 transitional challenges.
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
